Compare SERV & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SERV | KURA |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | United States |
| Employees | 380 | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 702.9M | 841.6M |
| IPO Year | N/A | 2015 |
| Metric | SERV | KURA |
|---|---|---|
| Price | $6.31 | $10.89 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 11 |
| Target Price | $17.67 | ★ $25.56 |
| AVG Volume (30 Days) | ★ 5.3M | 1.8M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,482,000.00 |
| Revenue This Year | $920.26 | $28.28 |
| Revenue Next Year | $184.90 | $106.37 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $5.78 | $5.45 |
| 52 Week High | $18.64 | $12.49 |
| Indicator | SERV | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 37.96 | 65.32 |
| Support Level | $5.78 | $8.72 |
| Resistance Level | $10.53 | $11.29 |
| Average True Range (ATR) | 0.45 | 0.47 |
| MACD | 0.03 | 0.13 |
| Stochastic Oscillator | 27.06 | 89.83 |
Serve Robotics Inc is developing next-generation robots for last-mile delivery services. It design, develop and operate low-emissions robots on AI-powered robotics mobility platform, that serve people in public spaces, starting with food delivery. Its first product is a zero-emission robot that serves people in public areas, Starting with food delivery. The Segment derives revenue from (i) services via the Companies robot fleet, including delivery, branding and experiential services, (ii) access to software developed for the robot fleet, including certain autonomous capabilities, and (iii) access to data collected by the robot fleet, including navigation-related data. The majority of the revenue is derived from robot delivery services and food delivery platforms.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.